OnKure Therapeutics, Inc. (OKUR)
NGM · Healthcare · Biotechnology
$3.10
-5.20%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$125.5M
Shares Outstanding
40.5M
Exchange
NGM
Currency
USD
About OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (15.5M) | (14.1M) | (15.6M) | (16.9M) |
| Net Income | (14.7M) | (13.5M) | (15.2M) | (15.3M) |
| Diluted EPS | $-1.09 | $-0.99 | $-1.11 | $-0.31 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (29.8M) | (36.9M) | (54.4M) | (63.0M) |
| Net Income | (29.5M) | (35.3M) | (52.7M) | (59.5M) |
| Diluted EPS | $-2.21 | $-2.65 | $-15.28 | N/A |